Pfizer has lifted the curtain on new Phase 3 data for its Janus kinase 1 (JAK1) inhibitor abrocitinib, revealing that the therapy met all of its co-primary and secondary endpoints in the treatment of moderate to severe...
Latest articles
FDA Approved Drug Products Approval List May 2019
FDA Approved Drug Products Approval List May 2019
Hoe scoort jouw e-mail marketing? Doe de E-mail Marketing Fit Test! #adv
Benieuwd naar de conditie van jouw e-mail marketing? Met de E-mail Marketing Fit Test van Spotler ontdek je in 10 stappen hoe effectief je bezig bent. De uitslag van de test wordt ingedeeld per onderwerp. Scoor jij...
Relugolix Combination Therapy Effective in Phase 3 Uterine Fibroids Trial
A phase 3 study evaluating the safety and efficacy of relugolix (Myovant Sciences), an investigational oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in combination with estradiol 1.0mg and...
Pfizer & Merck’s Inlyta combo becomes first FDA-approved anti-PD-L1 therapy for kidney cancer
The FDA has approved Bavencio (avelumab) in combination with Inlyta (axitinib) for the treatment of advanced renal cell carcinoma (RCC). The decision was announced by the drug’s co-developers Merck KGaA and Pfizer, and...
US FDA approves Lilly’s Cyramza to treat patients with hepatocellular carcinoma
Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has approved Cyramza (ramucirumab injection, 10 mg/mL solution), as a single agent, for the treatment of patients with
